Neuronetics, Inc. (STIM) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Neuronetics, Inc. is a global leader in neuroscience, primarily known for the NeuroStar Advanced Therapy System for treating major depressive disorder (MDD). A pivotal event for this reporting period is the full consolidation of Greenbrook TMS Inc., acquired on December 9, 2024. Greenbrook operates treatment centers across the U.S., significantly altering the company's revenue mix by adding direct clinic revenue.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $37.3 million | $18.5 million | $107.4 million | $52.4 million |
| Gross Profit | $17.1 million | $14.0 million | $50.6 million | $39.3 million |
| Gross Margin | 45.9% | 75.6% | 47.1% | 74.9% |
| Net Loss | $(9.4) million | $(13.3) million | $(31.9) million | $(31.0) million |
| Operating Cash Flow | N/A | N/A | $(21.3) million | $(22.4) million |
| Cash & Equivalents | $28.0 million (as of Sept 30, 2025) | |||
| Long-Term Debt | $65.7 million (net); $70.0 million principal outstanding |
Material Changes vs. Prior Period
- Revenue Surge: Revenue doubled (101% increase QoQ; 105% YTD) primarily due to the inclusion of $21.8 million in clinic revenue from Greenbrook for Q3 2025. This contrasts with Q3 2024, which had no clinic revenue.
- Margin Compression: Gross margin declined significantly from 75.6% to 45.9% in Q3. This is attributed to the lower-margin profile of the clinic business compared to the high-margin treatment session sales, alongside a decrease in treatment session revenue volume.
- Expense Management:
- Sales & Marketing: Remained flat ($11.8M vs $11.9M) despite Greenbrook inclusion, offset by reduced bad debt expense.
- G&A: Increased 49% ($11.1M vs $7.4M) due to Greenbrook integration costs, partially mitigated by realized synergies.
- R&D: Decreased 38% ($1.5M vs $2.4M) due to restructuring savings post-acquisition.
- Debt Restructuring: The company replaced its previous Solar Facility with a new Perceptive Credit Facility in July 2024. As of Q3 2025, $70 million is outstanding under this facility, maturing in July 2029.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash ($28.0M) and anticipated revenues are sufficient to fund operations for at least the next 12 months. The company maintains an ATM program with approximately $41.7 million remaining capacity.
- Outlook: The company anticipates operating losses will lessen in the near term due to revenue growth and cost efficiencies from the Greenbrook acquisition. Management targets achieving cash flow breakeven in the fourth quarter of 2025.
- Risks:
- Covenants: The Perceptive Facility includes minimum trailing revenue and liquidity covenants. Failure to meet these could trigger default.
- Integration: Risks associated with integrating Greenbrook's operations and realizing projected synergies.
- Reimbursement: Dependence on third-party payors (Medicare/Medicaid/Commercial) for clinic revenue, subject to audits and potential recoupments.
- Unusual Items: Q3 2024 included a $4.4 million loss on extinguishment of debt related to the Solar Facility, which is not present in Q3 2025.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 60% revenue contribution from Greenbrook clinic operations versus the core NeuroStar system sales.
- Covenant Compliance: Monitor quarterly revenue figures against the escalating minimum revenue covenants of the Perceptive Credit Facility.
- Cash Burn: Track the path to the stated Q4 2025 cash flow breakeven target given the current operating cash burn of ~$21M YTD.
- Debt Structure: Review the terms of the Perceptive Facility, specifically the variable interest rate (SOFR + 7%) and prepayment penalties.
- Reimbursement Rates: Assess any changes in reimbursement rates from Medicare or commercial payors that could impact the clinic margin profile.